SCHEMBL6474952

SCHEMBL6474952

O=S(=O)(Nc1cccc(CCOCc2csc(-c3ccccc3Cl)n2)c1)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.41
CYSLTR2 Q9NS75 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CTPS1 P17812 1/20 0.41
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
NPC1 O15118 1/20 0.35
CA2 P00918 1/20 0.35
HSD11B1 P28845 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KCNH2 Q12809 1/20 0.34
PTGS1 P23219 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474127 0.89 CYSLTR2 (0.43) CYSLTR2CYSLTR1ALDH1A1L3MBTL1CTPS1
SCHEMBL6482379 0.88 CTPS1 (0.43) PPARGCYSLTR2CYSLTR1CTPS1MAPT
SCHEMBL6475724 0.86 TP53 (0.42) CYSLTR2CYSLTR1CTPS1MAPTTP53
SCHEMBL6473587 0.84 TP53 (0.45) PPARGMAPTTP53SMN1; SMN2
SCHEMBL6474643 0.84 CYSLTR2 (0.39) PPARGCYSLTR2CYSLTR1CTPS1MAPT
SCHEMBL6479428 0.83 PPARA (0.41) PPARGCYSLTR2CYSLTR1CTPS1MAPT
SCHEMBL6483737 0.83 SHMT2 (0.46) PPARGCYSLTR2CYSLTR1ALDH1A1CTPS1
SCHEMBL6474743 0.83 TP53 (0.44) ALDH1A1TDP1L3MBTL1MAPTTP53
SCHEMBL6474761 0.81 CYSLTR2 (0.39) PPARGCYSLTR2CYSLTR1CTPS1MAPT
SCHEMBL6484833 0.79 CYSLTR2 (0.46) PPARGCYSLTR2CYSLTR1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 PPARG 256/4885CYSLTR2 4703/4885CYSLTR1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.